title: Effect of imidafenacin on the urodynamic parameters of patients with indwelling bladder catheters due to spinal cord injury.
abstract: METHODS
  A retrospective study.
  
  
  OBJECTIVE
  To investigate the effect of imidafenacin on the urodynamic parameters of patients with indwelling bladder catheters due to spinal cord injury (SCI).
  
  
  METHODS
  Spinal center (Tokyo, Japan).
  
  
  METHODS
  Imidafenacin was prescribed to 34 patients with SCI who had a low cystometric volume and/or detrusor compliance according to a urodynamic study. A low cystometric volume and detrusor compliance were defined as <200 ml and <20 ml cm-1H2O, respectively. The urodynamic study was repeated 4 weeks after imidafenacin was prescribed. When the urodynamic parameters did not improve in the follow-up study, the dose of imidafenacin was increased twofold. Then the urodynamic study was repeated 4 weeks thereafter. We compared the urodynamic parameters before and after imidafenacin treatment. Complications such as vesico-urethral reflux (VUR) and autonomic dysreflexia (AD) were documented.
  
  
  RESULTS
  Fifteen patients took 0.2 mg of imidafenacin daily, and 19 received 0.4 mg of imidafenacin daily. Imidafenacin increased the cystometric volume from 246.0 to 321.5 ml (median, P=0.002), detrusor compliance from 6.67 ml cm-1H2O to 8.98 ml cm-1H2O (median, P=0.012), and decreased the detrusor pressure from 37.0 cm H2O to 30.5 cm H2O (median, P=0.056). All three patients who had VUR fully recovered. Although 3 of 12 patients recovered from AD, 3 patients newly developed symptoms of AD. No patient withdrew from treatment due to adverse effects.
  
  
  CONCLUSIONS
  Imidafenacin is a safe drug that may improve the urodynamic parameters of patients with SCI, and it possibly alleviates bladder complications.
authors.affiliation: National Hospital Organization Murayama Medical Center, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Sugiyama
authors.affiliation: National Hospital Organization Murayama Medical Center, Tokyo, Japan.
authors.forename: O
authors.initials: O
authors.lastname: Uemura
authors.affiliation: National Hospital Organization Murayama Medical Center, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.affiliation: National Hospital Organization Murayama Medical Center, Tokyo, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Okisio
authors.affiliation: National Hospital Organization Murayama Medical Center, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Unai
authors.affiliation: Department of Rehabilitation Medicine, Keio University School of Medicine, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Liu
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013119:Spinal Cord Injuries / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects*; D014546:Urinary Catheterization / Q000009:adverse effects / Q000639:trends; D062885:Urinary Catheters / Q000009:adverse effects / Q000639:trends; D014563:Urodynamics / Q000187:drug effects* / Q000502:physiology
chemical_list: D007093:Imidazoles; C120953:imidafenacin